BOD SCIENCE LIMITED - Announcements

Market Cap $4.256M Add to my watchlist

Healthcare

Bod Science Limited is an Australia-based cannabis focused drug development and product... Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company’s segments include medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.More

NATURAL MEDICINE LEADERS

ASX-listed wellness consumer discretionary player Calmer Co (ASX:CCO) achieves record breaking 45% surge in eCommerce sales

Announcements

Filter Results

All Price Sensitive Only

BOD	Bod to benefit from UN decision to reclassify cannabis	PRICE SENSITIVE	04/12/20	527.24KB	Share
BOD	Bod broadens European footprint with binding purchase order	PRICE SENSITIVE	03/12/20	538.87KB	Share
BOD	Results of Annual General Meeting		25/11/20	568.08KB	Share
BOD	CEO Presentation to Annual General Meeting		25/11/20	2.7MB	Share
BOD	$1m binding purchase order received for Italian market entry	PRICE SENSITIVE	24/11/20	538.71KB	Share
BOD	Strong growth in medicinal cannabis sales continues	PRICE SENSITIVE	17/11/20	530.31KB	Share
BOD	Appendix 4G and Corporate Governance Statement		27/10/20	453.93KB	Share
BOD	Annual Report to shareholders		27/10/20	5.45MB	Share
BOD	Notice of Annual General Meeting and Proxy Form		23/10/20	967.51KB	Share
BOD	Bod launches CBD products in the Netherlands	PRICE SENSITIVE	20/10/20	533.14KB	Share
BOD	Change of Director's Interest Notice		19/10/20	168.25KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	14/10/20	806.99KB	Share
BOD	Date of Annual General Meeting		12/10/20	509.98KB	Share
BOD	Record medicinal cannabis purchase orders achieved in Q1	PRICE SENSITIVE	07/10/20	593.46KB	Share
BOD	Bod achieves 'Generally Recognised as Safe' (GRAS) status	PRICE SENSITIVE	23/09/20	539.56KB	Share
BOD	Regulatory shift unlocks large market opportunity for Bod	PRICE SENSITIVE	10/09/20	539.5KB	Share
BOD	Change in substantial holding		03/09/20	94.2KB	Share
BOD	Strategic agreement to streamline UK cannabis prescriptions	PRICE SENSITIVE	01/09/20	540.72KB	Share
BOD	Financial year 2020 results presentation	PRICE SENSITIVE	21/08/20	2.59MB	Share
BOD	Record FY2020 financial result positions Bod for growth	PRICE SENSITIVE	21/08/20	577.83KB	Share
BOD	Appendix 4E and full year statutory accounts	PRICE SENSITIVE	21/08/20	1.23MB	Share
BOD	Change in substantial holding		18/08/20	169.24KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	21/07/20	833.58KB	Share
BOD	Additional information - Australian medicinal cannabis study		20/07/20	464.14KB	Share
BOD	Australia-wide medicinal cannabis study commenced	PRICE SENSITIVE	16/07/20	483.03KB	Share
BOD	Bod delivers record fourth quarter revenue of $2.5 million	PRICE SENSITIVE	02/07/20	540.36KB	Share
BOD	Bod continues to achieve strong revenue growth in FY2020	PRICE SENSITIVE	04/06/20	496.95KB	Share
BOD	Continued upward trajectory in prescription volumes	PRICE SENSITIVE	20/05/20	557.32KB	Share
BOD	First prescriptions received from Project Twenty21 patients	PRICE SENSITIVE	12/05/20	490.44KB	Share
BOD	Record $1.43m purchase order to strengthen FY2020 revenue	PRICE SENSITIVE	06/05/20	545.51KB	Share
BOD	First medicinal cannabis prescriptions received in the UK	PRICE SENSITIVE	04/05/20	482.83KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	21/04/20	789.82KB	Share
BOD	Bod launches 4 new CBD products under CBII brand in the UK	PRICE SENSITIVE	14/04/20	493.05KB	Share
BOD	Corporate Update - Business growth continues	PRICE SENSITIVE	06/04/20	608.32KB	Share
BOD	Ceasing to be a substantial holder		03/04/20	45.77KB	Share
BOD	Bod receives $851,000 R&D Tax Incentive Refund	PRICE SENSITIVE	01/04/20	482.98KB	Share
BOD	CEO Interview		31/03/20	584.57KB	Share
BOD	Swisse Wellness and Bod launch first hemp products	PRICE SENSITIVE	30/03/20	476.27KB	Share
BOD	Half yearly financial statements and Appendix 4D	PRICE SENSITIVE	28/02/20	2.51MB	Share
BOD	Bod's medicinal cannabis sales off to strong start in CY2020	PRICE SENSITIVE	18/02/20	613.49KB	Share
BOD	Managing Director audio interview		13/02/20	642.89KB	Share
BOD	Import permit received to expand medicinal cannabis products	PRICE SENSITIVE	11/02/20	482.82KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/01/20	714.85KB	Share
BOD	Change of Director's Interest and Final Director's Interest		19/12/19	433.24KB	Share
BOD	Resignation of Alternate Director		18/12/19	461.05KB	Share
BOD	Bod and H&H Group launch first CBD products in the UK	PRICE SENSITIVE	16/12/19	526.27KB	Share
BOD	Bod enters research collaboration with UniSA	PRICE SENSITIVE	12/12/19	476.12KB	Share
BOD	Corporate Presentation		10/12/19	3.25MB	Share
BOD	Change of Director Interest Notices		10/12/19	652.07KB	Share
BOD	Appendix 3B		10/12/19	594.21KB	Share
BOD	Optimised Board commences following shareholder approval		25/11/19	320.1KB	Share
BOD	Change of Director's Interest - Mark Masterson		25/11/19	212.69KB	Share
BOD	Appendix 3Z - Simon Taylor		12/11/19	192.56KB	Share
BOD	Appendix 3X - Mark Masterson		12/11/19	190.86KB	Share
BOD	Section 708A Cleansing Notice		12/11/19	177.46KB	Share
BOD	Appendix 3B		12/11/19	594.33KB	Share
BOD	Results of Annual General Meeting		11/11/19	354.32KB	Share
BOD	CEO Presentation to Annual General Meeting	PRICE SENSITIVE	11/11/19	1.96MB	Share
BOD	Bod to take part in European medicinal cannabis project	PRICE SENSITIVE	08/11/19	388.19KB	Share
BOD	Change of Director's Interest Notice		05/11/19	239.69KB	Share
BOD	Quarterly activities report and Appendix 4C	PRICE SENSITIVE	14/10/19	643.98KB	Share
BOD	Appendix 4G and Corporate Governance Statement		11/10/19	518.15KB	Share
BOD	Annual Report to shareholders		10/10/19	3.92MB	Share
BOD	Notice of Annual General Meeting/Proxy Form		10/10/19	532.64KB	Share
BOD	MediCabillis continues solid prescription growth	PRICE SENSITIVE	03/10/19	467.22KB	Share
BOD	Section 708A Cleansing Notice		23/09/19	208.69KB	Share
BOD	Appendix 3B - Exercise of Options		23/09/19	537.97KB	Share
BOD	Leading pharmaceutical executive to be appointed as Chairman		23/09/19	382.94KB	Share
BOD	Medicinal cannabis sales jump 95% month on month	PRICE SENSITIVE	03/09/19	383.41KB	Share
BOD	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	30/08/19	1.32MB	Share
BOD	Becoming a substantial holder		15/08/19	184.58KB	Share
BOD	Hong Kong roadshow with H&H Group	PRICE SENSITIVE	15/08/19	6.22MB	Share
BOD	Novel delivery system to combat skin aging process	PRICE SENSITIVE	14/08/19	373.59KB	Share
BOD	Amended Appendix 3Y		12/08/19	313.19KB	Share
BOD	Change in substantial holding notices		06/08/19	1.56MB	Share
BOD	Change of Director Interest Notices		06/08/19	468.05KB	Share
BOD	Section 708A Cleansing Notice		06/08/19	106.8KB	Share
BOD	Appendix 3B		06/08/19	589.98KB	Share
BOD	Bod raises $1.2m via Board and management options exercise	PRICE SENSITIVE	06/08/19	359.66KB	Share
BOD	Bod enters UK Market with distribution deal with PCCA Ltd	PRICE SENSITIVE	29/07/19	375.7KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/07/19	646.44KB	Share
BOD	Significant growth in medical cannabis prescriptions	PRICE SENSITIVE	25/07/19	374.09KB	Share
BOD	Ceasing to be a substantial holder		23/07/19	172.5KB	Share
BOD	Change in substantial holding		23/07/19	166.27KB	Share
BOD	Becoming a substantial holder		23/07/19	973.08KB	Share
BOD	Initial Director's Interest Notices		23/07/19	245.4KB	Share
BOD	Section 708A Cleansing Notice and Appendix 3B		23/07/19	667.17KB	Share
BOD	Bod appoints two Directors following NewH2 Investment		23/07/19	391.83KB	Share
BOD	New H2 makes strategic investment in Bod Australia	PRICE SENSITIVE	19/07/19	205.08KB	Share
BOD	Trading Halt	PRICE SENSITIVE	17/07/19	349.87KB	Share
BOD	Distribution agreement to bolster medicinal cannabis sales	PRICE SENSITIVE	21/06/19	618.79KB	Share
BOD	Bod to supply medicinal cannabis for a landmark PTSD trial	PRICE SENSITIVE	04/06/19	619.53KB	Share
BOD	Ceasing to be a substantial holder		24/05/19	156.43KB	Share
BOD	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/04/19	722.62KB	Share
BOD	Change in substantial holding		01/04/19	170.35KB	Share
BOD	Clinical Trial demonstrates Bod's CBD Wafer superiority	PRICE SENSITIVE	26/03/19	380.64KB	Share
BOD	Bod progresses European expansion following LOI with Tilman	PRICE SENSITIVE	11/03/19	373.77KB	Share
BOD	Ceasing to be a substantial holder		06/03/19	271.15KB	Share
BOD	Bod expands medicinal cannabis product suite	PRICE SENSITIVE	01/03/19	397.58KB	Share
BOD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	1.33MB	Share

BOD Bod to benefit from UN decision to reclassify cannabis
04/12/20	PRICE SENSITIVE	527.24KB	Share
BOD Bod broadens European footprint with binding purchase order
03/12/20	PRICE SENSITIVE	538.87KB	Share
BOD Results of Annual General Meeting
25/11/20		568.08KB	Share
BOD CEO Presentation to Annual General Meeting
25/11/20		2.7MB	Share
BOD $1m binding purchase order received for Italian market entry
24/11/20	PRICE SENSITIVE	538.71KB	Share
BOD Strong growth in medicinal cannabis sales continues
17/11/20	PRICE SENSITIVE	530.31KB	Share
BOD Appendix 4G and Corporate Governance Statement
27/10/20		453.93KB	Share
BOD Annual Report to shareholders
27/10/20		5.45MB	Share
BOD Notice of Annual General Meeting and Proxy Form
23/10/20		967.51KB	Share
BOD Bod launches CBD products in the Netherlands
20/10/20	PRICE SENSITIVE	533.14KB	Share
BOD Change of Director's Interest Notice
19/10/20		168.25KB	Share
BOD Quarterly Activities Report and Appendix 4C
14/10/20	PRICE SENSITIVE	806.99KB	Share
BOD Date of Annual General Meeting
12/10/20		509.98KB	Share
BOD Record medicinal cannabis purchase orders achieved in Q1
07/10/20	PRICE SENSITIVE	593.46KB	Share
BOD Bod achieves 'Generally Recognised as Safe' (GRAS) status
23/09/20	PRICE SENSITIVE	539.56KB	Share
BOD Regulatory shift unlocks large market opportunity for Bod
10/09/20	PRICE SENSITIVE	539.5KB	Share
BOD Change in substantial holding
03/09/20		94.2KB	Share
BOD Strategic agreement to streamline UK cannabis prescriptions
01/09/20	PRICE SENSITIVE	540.72KB	Share
BOD Financial year 2020 results presentation
21/08/20	PRICE SENSITIVE	2.59MB	Share
BOD Record FY2020 financial result positions Bod for growth
21/08/20	PRICE SENSITIVE	577.83KB	Share
BOD Appendix 4E and full year statutory accounts
21/08/20	PRICE SENSITIVE	1.23MB	Share
BOD Change in substantial holding
18/08/20		169.24KB	Share
BOD Quarterly Activities Report and Appendix 4C
21/07/20	PRICE SENSITIVE	833.58KB	Share
BOD Additional information - Australian medicinal cannabis study
20/07/20		464.14KB	Share
BOD Australia-wide medicinal cannabis study commenced
16/07/20	PRICE SENSITIVE	483.03KB	Share
BOD Bod delivers record fourth quarter revenue of $2.5 million
02/07/20	PRICE SENSITIVE	540.36KB	Share
BOD Bod continues to achieve strong revenue growth in FY2020
04/06/20	PRICE SENSITIVE	496.95KB	Share
BOD Continued upward trajectory in prescription volumes
20/05/20	PRICE SENSITIVE	557.32KB	Share
BOD First prescriptions received from Project Twenty21 patients
12/05/20	PRICE SENSITIVE	490.44KB	Share
BOD Record $1.43m purchase order to strengthen FY2020 revenue
06/05/20	PRICE SENSITIVE	545.51KB	Share
BOD First medicinal cannabis prescriptions received in the UK
04/05/20	PRICE SENSITIVE	482.83KB	Share
BOD Quarterly Activities Report and Appendix 4C
21/04/20	PRICE SENSITIVE	789.82KB	Share
BOD Bod launches 4 new CBD products under CBII brand in the UK
14/04/20	PRICE SENSITIVE	493.05KB	Share
BOD Corporate Update - Business growth continues
06/04/20	PRICE SENSITIVE	608.32KB	Share
BOD Ceasing to be a substantial holder
03/04/20		45.77KB	Share
BOD Bod receives $851,000 R&D Tax Incentive Refund
01/04/20	PRICE SENSITIVE	482.98KB	Share
BOD CEO Interview
31/03/20		584.57KB	Share
BOD Swisse Wellness and Bod launch first hemp products
30/03/20	PRICE SENSITIVE	476.27KB	Share
BOD Half yearly financial statements and Appendix 4D
28/02/20	PRICE SENSITIVE	2.51MB	Share
BOD Bod's medicinal cannabis sales off to strong start in CY2020
18/02/20	PRICE SENSITIVE	613.49KB	Share
BOD Managing Director audio interview
13/02/20		642.89KB	Share
BOD Import permit received to expand medicinal cannabis products
11/02/20	PRICE SENSITIVE	482.82KB	Share
BOD Quarterly Activities Report and Appendix 4C
28/01/20	PRICE SENSITIVE	714.85KB	Share
BOD Change of Director's Interest and Final Director's Interest
19/12/19		433.24KB	Share
BOD Resignation of Alternate Director
18/12/19		461.05KB	Share
BOD Bod and H&H Group launch first CBD products in the UK
16/12/19	PRICE SENSITIVE	526.27KB	Share
BOD Bod enters research collaboration with UniSA
12/12/19	PRICE SENSITIVE	476.12KB	Share
BOD Corporate Presentation
10/12/19		3.25MB	Share
BOD Change of Director Interest Notices
10/12/19		652.07KB	Share
BOD Appendix 3B
10/12/19		594.21KB	Share
BOD Optimised Board commences following shareholder approval
25/11/19		320.1KB	Share
BOD Change of Director's Interest - Mark Masterson
25/11/19		212.69KB	Share
BOD Appendix 3Z - Simon Taylor
12/11/19		192.56KB	Share
BOD Appendix 3X - Mark Masterson
12/11/19		190.86KB	Share
BOD Section 708A Cleansing Notice
12/11/19		177.46KB	Share
BOD Appendix 3B
12/11/19		594.33KB	Share
BOD Results of Annual General Meeting
11/11/19		354.32KB	Share
BOD CEO Presentation to Annual General Meeting
11/11/19	PRICE SENSITIVE	1.96MB	Share
BOD Bod to take part in European medicinal cannabis project
08/11/19	PRICE SENSITIVE	388.19KB	Share
BOD Change of Director's Interest Notice
05/11/19		239.69KB	Share
BOD Quarterly activities report and Appendix 4C
14/10/19	PRICE SENSITIVE	643.98KB	Share
BOD Appendix 4G and Corporate Governance Statement
11/10/19		518.15KB	Share
BOD Annual Report to shareholders
10/10/19		3.92MB	Share
BOD Notice of Annual General Meeting/Proxy Form
10/10/19		532.64KB	Share
BOD MediCabillis continues solid prescription growth
03/10/19	PRICE SENSITIVE	467.22KB	Share
BOD Section 708A Cleansing Notice
23/09/19		208.69KB	Share
BOD Appendix 3B - Exercise of Options
23/09/19		537.97KB	Share
BOD Leading pharmaceutical executive to be appointed as Chairman
23/09/19		382.94KB	Share
BOD Medicinal cannabis sales jump 95% month on month
03/09/19	PRICE SENSITIVE	383.41KB	Share
BOD Appendix 4E and Full Year Statutory Accounts
30/08/19	PRICE SENSITIVE	1.32MB	Share
BOD Becoming a substantial holder
15/08/19		184.58KB	Share
BOD Hong Kong roadshow with H&H Group
15/08/19	PRICE SENSITIVE	6.22MB	Share
BOD Novel delivery system to combat skin aging process
14/08/19	PRICE SENSITIVE	373.59KB	Share
BOD Amended Appendix 3Y
12/08/19		313.19KB	Share
BOD Change in substantial holding notices
06/08/19		1.56MB	Share
BOD Change of Director Interest Notices
06/08/19		468.05KB	Share
BOD Section 708A Cleansing Notice
06/08/19		106.8KB	Share
BOD Appendix 3B
06/08/19		589.98KB	Share
BOD Bod raises $1.2m via Board and management options exercise
06/08/19	PRICE SENSITIVE	359.66KB	Share
BOD Bod enters UK Market with distribution deal with PCCA Ltd
29/07/19	PRICE SENSITIVE	375.7KB	Share
BOD Quarterly Activities Report and Appendix 4C
26/07/19	PRICE SENSITIVE	646.44KB	Share
BOD Significant growth in medical cannabis prescriptions
25/07/19	PRICE SENSITIVE	374.09KB	Share
BOD Ceasing to be a substantial holder
23/07/19		172.5KB	Share
BOD Change in substantial holding
23/07/19		166.27KB	Share
BOD Becoming a substantial holder
23/07/19		973.08KB	Share
BOD Initial Director's Interest Notices
23/07/19		245.4KB	Share
BOD Section 708A Cleansing Notice and Appendix 3B
23/07/19		667.17KB	Share
BOD Bod appoints two Directors following NewH2 Investment
23/07/19		391.83KB	Share
BOD New H2 makes strategic investment in Bod Australia
19/07/19	PRICE SENSITIVE	205.08KB	Share
BOD Trading Halt
17/07/19	PRICE SENSITIVE	349.87KB	Share
BOD Distribution agreement to bolster medicinal cannabis sales
21/06/19	PRICE SENSITIVE	618.79KB	Share
BOD Bod to supply medicinal cannabis for a landmark PTSD trial
04/06/19	PRICE SENSITIVE	619.53KB	Share
BOD Ceasing to be a substantial holder
24/05/19		156.43KB	Share
BOD Quarterly Activities Report and Appendix 4C
30/04/19	PRICE SENSITIVE	722.62KB	Share
BOD Change in substantial holding
01/04/19		170.35KB	Share
BOD Clinical Trial demonstrates Bod's CBD Wafer superiority
26/03/19	PRICE SENSITIVE	380.64KB	Share
BOD Bod progresses European expansion following LOI with Tilman
11/03/19	PRICE SENSITIVE	373.77KB	Share
BOD Ceasing to be a substantial holder
06/03/19		271.15KB	Share
BOD Bod expands medicinal cannabis product suite
01/03/19	PRICE SENSITIVE	397.58KB	Share
BOD Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	1.33MB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 2.4¢		Change 0.000(0.00%)		Mkt cap ! $4.256M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

BOD (ASX) Chart

Day chart unavailable

BOD SCIENCE LIMITED - Announcements

Announcements

Top Stories